News and press releases covering LASEROPTEK devices and technology are available in this corner.

Keep up to date with our global presence in the medical and aesthetics here.

  • LASEROPTEK Receives PMDA Approval for PALLAS™

    SEOUL, Republic of Korea – January 6, 2021 – LASEROPTEK Co., Ltd. has announced PMDA approval for its PALLAS™ laser system. The PMDA, or Pharmaceuticals and Medical Devices Agency, is a pharmaceutical regulatory authority in Japan renowned for its strict licensing procedures. With that, PALLAS is the first-ever Korean device to be approved by the PMDA for treating chronic skin conditions including vitiligo, psoriasis, and atopic dermatitis. Most recently, LASEROPTEK’s PicoLO, HELIOS III, and LOTUS III laser systems also obtained licensing from Australia’s own regulatory body for medicines, medical devices, and diagnostics, the Therapeutic Good Administration (TGA). PALLAS is the world’s first solid-state Nd:YAG laser system that integrates 308nm and 311nm wavelengths designed to treat such conditions both effectively and safely – without the use of anesthetics – for people of all ages. PALLAS also reduces the cost of maintenance for users while operating the device daily. Following PMDA approval of PALLAS, C.J. Lee, CEO of LASEROPTEK, said the company is confident it can accelerate entry into global medical and aesthetic markets with cutting-edge laser systems supported by strong roots in R&D, and firm establishment of the company’s global network infrastructure. The clinical efficacies of PALLAS are featured in the Journal of American Medical Association (JAMA) Dermatology, Journal of the American Academy of Dermatology (JAAD), Wiley’s Photodermatology, Photoimmunology & Photomedicine, among other prestigious publications. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about PALLAS and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com.

    VIEW MORE +
  • LASEROPTEK Receives CE Mark for PicoLO Premium™, Opening the Door to the EU Market

    SEOUL, Republic of Korea - February 19, 2021 - A global developer and manufacturer of aesthetic and medical laser systems, LASEROPTEK Co., Ltd. is pleased to announce European CE Marking for its latest Picosecond Nd: YAG laser, PicoLO Premium™. Representing a significant upgrade from PicoLO which launched in 2018, PicoLO Premium takes efficacy and user convenience to the next level via a powerful lineup of next-generation handpieces. Handpieces include both a 1064nm and a 532nm Diffractive Optical Element (DOE) based fractional handpieces, a Collimator handpiece, a Zoom handpiece, and an exclusive S20 handpiece with a wider spot size for fast and efficient treatments. Boasting powerful and stable beam profiles, PicoLO Premium’s DOE fractional handpieces are also upgraded with a new look and branding. The “Dia FX®” 1064nm  ‘S’ handpiece enables highly delicate and defined area treatments with a new level of precision and efficacy. It also features a new and simple twist-and-treat function that allows users to quickly and easily select from three distinct laser energy penetration depths. Efficacious picosecond pulses targeting the deep dermis, upper dermis, and epidermis can now be accurately and repeatedly delivered helping clinicians create amazing outcomes. Additionally, the Dia FX 1064 handpiece also features two spot sizes for treating indications that require precision and customization. Commenting on PicoLO Premium’s CE Mark and incorporation into the company’s extensive line-up of cutting-edge laser systems, C.J. Lee, CEO of LASEROPTEK  said “PicoLO Premium’s CE Mark allows us to export a world-class laser that meets the exceptional standards and demands of European clinicians in their  respective regions.” “The company is well-equipped to face the rapidly changing medical and aesthetic market head-on as a pioneer in Europe and other global regions,” added Mr. Lee. Evidencing PicoLO Premium’s treatment efficacy for various indications, a recent study published in the Journal of European Academy of Dermatology and  Venereology concluded that the PicoLO Premium with the Dia FX 1064nm handpiece was proven to be more effective in treating acne scars with noticeable clinical improvements to skin pores and texture when compared to the non-ablative 1550nm Er: Glass laser. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about the new PicoLO Premium and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com.

    VIEW MORE +
  • Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser

    Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser. Awarded in the commercialization technology category for the development of a diagnosis/treatment system based on a wavelength tunable ultra-fast switching laser. Please pay more attention to PicoLO laser, which has succeeded in commercialization model with stabilized technology.

    2020.11.18

  • LASEROPTEK Co. Ltd., Announces U.S. Launch of PALLAS, First-of-its-Kind Solid State UVB Medical Dermatology Laser

    LASEROPTEK's PALLAS Solid-State 311nm UVB Laser is Clinically- Proven & FDA Cleared to Treat Vitiligo, Psoriasis, Atopic Dermatitis and Leukodermas SEOUL, Republic of Korea, Aug. 12, 2020 /PRNewswire/ -- LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology, is pleased to announce the launch of its PALLAS Solid-State 311nm UVB laser in the United States.  The efficacious and safe PALLAS laser is FDA cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma. LASEROPTEK's PALLAS Solid-State UVB Laser FDA Cleared For Treating Vitiligo, Psoriasis, Atopic Dermatitis and Leukodermas. Available In 308nm or 311nm Models. Solid-State Design Negates the Need For Costly Gas and Electrode Replacements Driving a Strong Return On Investment. PALLAS is Safe, Efficacious and With a Low Cost of Ownership. PALLAS is the fifth LASEROPTEK laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world's first solid-state UVB laser delivering efficacious and safer treatment for a variety of skin conditions that collectively affect close to a billion people worldwide. PALLAS features unique technology improvements over 308 nanometer excimer lasers currently used to treat vitiligo, psoriasis, atopic dermatitis and leukodermas.  PALLAS provides physicians flexibility by allowing the choice of either 308 or 311 nanometer versions.  Both wavelength choices feature PALLAS' unique, solid-state technology eliminating the need for costly and time-consuming excimer gas and electrode replacements no matter which wavelength is chosen.  This reduction in operating costs is a desired and welcomed benefit in today's challenging market environment. Dr. Peter Jenkin, owner of Dermatology Associates of Seattle since 2010, is a respected expert in the treatment of pigmentation related skin disorders and is among the first health care providers offering treatments using PALLAS.  "I chose LASEROPTEK's PALLAS UVB laser with the 311nanometer output option given its efficacy and higher safety profile for my patients.  I had been aware of research for a few years that the 311nm wavelength might be the best option," this according to Dr. Jenkin. "I also appreciate the solid-state technology that negates the need for costly and time-consuming service calls to replace electrodes and excimer gas," added Dr. Jenkin. Commenting on the launch of PALLAS in the U.S., CJ Lee, CEO of LASEROPTEK said, "LASEROPTEK, in collaboration with our U.S. partners Gale Force Aesthetics and Laser Service Solutions, is deeply committed to developing, selling and servicing advanced laser devices to the U.S. medical and cosmetic dermatology market that improve safety, efficacy and economics for our physician customers and their patients.  PALLAS is a great example of this commitment.  We very much appreciate Dr. Jenkin's trust in PALLAS to provide his patients with safe, efficacious and comfortable treatments.  We look forward to a long-term relationship with Dr. Jenkin and the entire staff at Dermatology Associates of Seattle." Jayson Jonsson, CEO of Gale Force Aesthetics, the exclusive distributor of LASEROPTEK lasers in the U.S. adds, "We are excited and proud to partner with LASEROPTEK to launch PALLAS in the U.S.  Physicians need safe and effective treatment options for difficult-to-treat skin conditions like vitiligo, psoriasis, atopic dermatitis and leukodermas. We are confident that this device will provide a much-needed option to physicians and deliver great results for patients." To learn more about LASEROPTEK's world-class lineup of lasers for aesthetic and medical dermatology, please visit www.laseroptek.com.  To purchase or lease a LASEROPTEK laser in the United States, please visit www.galeforceaesthetics.com or contact Jayson Jonsson at +1(925) 705-6206.  To learn more about Dermatology Associates of Seattle's extensive offering of medical and aesthetic treatments, please visit www.daseattle.com or call +1(206) 267-2100. About LASEROPTEK Co., Ltd. LASEROPTEK is a global technology-driven medical device company in the aesthetic and medical laser market. Founded in 2000 and with its in-house R&D capabilities, LASEROPTEK introduces safe, stable and highly efficacious laser systems merging advanced laser technology with clinical efficacy. About Dermatology Associates of Seattle Our mission is to promote optimal health of the skin by providing the highest quality, comprehensive, personalized dermatologic care. Our team members are committed to carrying out this mission in a respectful and enriching work environment that fosters professional development. About Gale Force Aesthetics, LLC Gale Force Aesthetics partners with best-in-class manufacturers – deploying a nationwide team of independent sales consultants that drive sales while building a strong reputation of excellence for their partners. Media Contacts:Helena Lee245160@email4pr.com+82.2.6954.1895 Christopher Dalton245160@email4pr.com+1.619.609.4757 SOURCE LASEROPTEK Co. Ltd. https://www.prnewswire.com/news-releases/laseroptek-co-ltd-announces-us-launch-of-pallas-first-of-its-kind-solid-state-uvb-medical-dermatology-laser-301110706.html

    2020.08.12

  • Meet Dr. Jung-min Bae, "the Master of Vitiligo Treatment”

    [Prof. Huh’s Talk on Dermatologic Medical Devices] LaserOptek ③Voice from the Field (Fin) Prof. Chang Hun Huh, at the department of dermatology of Seoul National University Bundang Hospital, visited Dr. Jung-min Bae of the Heal House Skin Clinic, who is expertly treating many vitiligo patients with LaserOptek's Pallas laser. (Prof. Huh on the left and Dr. Bae on the right.) When I started this column, I've decided to write it on the site, not on the desk. Prof. Jung-min Bae, who appeared like a rising star in dermatologic journals in recent years, told me that he had left university hospital and opened a private clinic. "Heal House Skin Clinic" was the name of it and its meaning is "a healing house for patients." He has been globally known as an expert in treating vitiligo with Pallas laser. I interviewed him in person and listened to his story. - Why did you suddenly open a private clinic and left a university hospital, where is easy to conduct numerous researches? It is because I wanted to encounter more vitiligo patients, closely. I’ve accumulated clinical and research experiences on vitiligo treatment at a university hospital. Being able to conduct various research was a great benefit of working at a university hospital, but there were some cons. I always felt inconvenience for not seeing more patients due to limited consultation hours. Also, focusing on vitiligo, my area of expertise, was not easy because of the many general dermatologic patients. That’s why I decided to open a vitiligo specialized clinic based on my experience so far. I developed a “vitiligo total care center” with Pallas laser which can treat vitiligo effectively, admission and operating rooms for surgical procedures, vitiligo special nurses, and special skincare programs for vitiligo. Dr. Bae who is well known as "the master of vitiligo treatment” has recently opened a private clinic focusing on treating vitiligo, while communicating with a lot more patients and providing safe and effective treatments. - What is the most effective vitiligo treatment? The basic treatments for vitiligo are NBUVB and Pallas laser. Especially, Pallas laser has a much more beneficial to small size or facial lesion because it can skip the irradiation of UV rays on the normal skin. - Is there any pain or side effect when using the laser on sensitive areas of skin like around the eyes? Generally, there are no pain or side effects serious enough to stop the treatment. Wavelengths of Pallas laser do not penetrate through whole layers of skin. Also, you don’t have to worry about it since when you close your eyes, the pupils move upward and be covered safely under the frontal bone. Even if the laser is accidentally irradiated on the eyes, there might be temporal damage to cornea or lens, but no permanent damage to the retina or optic nerves has been reported. As preventing accidents is essential, I am putting every effort into safety when doing laser procedures. Alopecia totalis treated by Pallas laser. A: Before, B: After 3 months, C: After 7 months (photos from Laser in Medical Science 2020;35:999-1002) - Are there any differences in the effects of Pallas laser treatment by age groups? It is more effective if the patient is younger. Pallas laser can be used safer and easier even on patients with claustrophobia or children who cannot use cabinet type UV treatment devices. Besides, it is a safe and effective treatment for not only children and elderly but also even pregnant women. - What are treatment cycles and post-treatment care? In general, 2 sessions per week are basic, but it might be adjustable 1~3/week according to the cases. Pallas laser treatment does not have any downtime, so patients can return to daily life right after the procedure. However, UV exposure should be avoided. - What other diseases can be treated with Pallas laser? Pallas has already been in use for vitiligo and psoriasis. Also, it seems to be highly effective in atopic dermatitis and alopecia areata in my personal experience so far. Indeed, Pallas laser treatment has no pain at all, so it is expected to be the new hope for the pediatric alopecia areata patient who is not easy to get injected due to pain. - What are the differences between Pallas laser and previous Excimer lasers? A wavelength of the classic Excimer laser is 308nm, and that of Pallas laser is 311nm. The difference between wavelengths is minimal, but the biologic difference is not small. According to the previous research data conducted at the university hospital, minimal erythema dose of Pallas laser was 1.7 times higher and penetrated deeper than Excimer, resulting in greater treatment effects. Tag#PallasLaser#Laseroptek http://www.k-health.com

    2020.08.01